Chemoembolization, Therapeutic
"Chemoembolization, Therapeutic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Administration of antineoplastic agents together with an embolizing vehicle. This allows slow release of the agent as well as obstruction of the blood supply to the neoplasm.
| Descriptor ID |
D016461
|
| MeSH Number(s) |
E02.520.360.150 E02.926.500.150
|
| Concept/Terms |
Chemoembolization, Therapeutic- Chemoembolization, Therapeutic
- Therapeutic Chemoembolization
- Chemoembolizations, Therapeutic
- Therapeutic Chemoembolizations
|
Below are MeSH descriptors whose meaning is more general than "Chemoembolization, Therapeutic".
Below are MeSH descriptors whose meaning is more specific than "Chemoembolization, Therapeutic".
This graph shows the total number of publications written about "Chemoembolization, Therapeutic" by people in this website by year, and whether "Chemoembolization, Therapeutic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 2 | 3 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 2 | 3 |
| 2020 | 3 | 0 | 3 |
| 2022 | 2 | 0 | 2 |
| 2023 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemoembolization, Therapeutic" by people in Profiles.
-
Phase II Trial of Lung Chemoembolization. J Vasc Interv Radiol. 2023 12; 34(12):2090-2092.
-
Management of Intermediate-Stage Hepatocellular Carcinoma: Systemic Versus Locoregional Therapy. Surg Oncol Clin N Am. 2024 01; 33(1):159-172.
-
Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis. J Med Econ. 2023 Jan-Dec; 26(1):1061-1071.
-
Transarterial Radioembolization versus Transarterial Chemoembolization Plus Percutaneous Ablation for Unresectable, Solitary Hepatocellular Carcinoma of =3 cm: A Propensity Score-Matched Study. J Vasc Interv Radiol. 2022 12; 33(12):1570-1577.e1.
-
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 2022 06; 10(6).
-
Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years? Clin Liver Dis. 2020 11; 24(4):681-700.
-
Hepatocellular Carcinoma: A Contemporary Approach to Locoregional Therapy. Am J Gastroenterol. 2020 11; 115(11):1733-1736.
-
Lack of Technique Standardization Limits Evaluation of Toxicity following Transarterial Chemoembolization. J Vasc Interv Radiol. 2020 08; 31(8):1300-1301.
-
Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020 04; 18(4):974-983.
-
Nonresectional regional therapies for metastatic colorectal cancer to the liver. J Surg Oncol. 2019 Apr; 119(5):636-641.